Abstract:Objective To evaluate the clinical efficacy and safety of iMliximab (IFX) in the treatment of Crohn's disease (CD).Methods From February 2009 to March 2013,the clinical data of 62 CD patients with IFX treatment were retrospectively analyzed.At week 14th after IFX injection and the end of follow-up of this study (March 2013) were two observation points.At week 14th after IFX injection (three times of IFX injection),C reactive protein (CRP) level,Crohn's disease activity index (CDAI) score and clinical remission were investigated.At the end of follow-up,clinical remission,fistula closure,mucosal healing and side effects were inspected.Normal distribution data were expressed as 2±s,which were compared with t test.Non normal distribution data were expressed as M (QL-QU) and compared with Wilcoxon test.Results Four cases without complete three times of IFX injection and one case lost to follow-up were eliminated.And nine postoperation cases with IFX treatment to prevent recurrence after surgery were excluded.A total of 48 cases of CD in active period were enrolled in this study on efficacy.At week 14th,CRP level of 48 patients [1.9(0.5,5.4) mg/L]decreased compared with that before treatment [28.9(6.4,51.1) mg/L] (Z=-5.468,P＜0.01);CDAI score (87.0±35.8) also decreased compared with that before treatment (245.1±59.1) (t=18.579,P＜0.01).At week 14th,46 patients in active period achieved clinical remission and the remission rate was 95.8％.By the end of follow-up,38 patients were still in remission period and the remission rate was 79.2％.Among 26 patients with anal fistula before IFX treatment,seven cases (26.9％) were completely closed,17 cases (65.4％) was partially closed and two cases was responseless.Fifteen patients were reviewed by colonoscopic examination after more than six times of IFX treatment.The median of simple endoscopic score for Crohn's disease (SES-CD) was 3 (0,5)after treatment,which decreased compared with that before treatment (8(7,9),Z=-3.306,P=0.001).Twenty-two of 48 cases in active period received,step-up strategy and 26 cases received with top-down strategy.At week 14th,20 cases (90.9％) of group with step-up strategy and 26 cases (100.0％) of group with top-down strategy were in remission period.By the end of follow-up,14 cases (63.6％) of group with step-up strategy and 24 cases (92.3％) of group with top down strategy maintained remission.Among 26 cases with anal fistula,two cases without response were treated with step-up strategy and seven cases with complete closure were all with top-down strategy.Among 62 patients,five had side effects,three of whom had acute infusion reaction,one had delayed infusion reaction and the other had anemia.Conclusions IFX had good clinical efficacy in controlling inflammation,inducing clinical remission,promoting fistula closure and mucosal healing in CD patients.For some CD patients with high risk,the initial top-down strategy showed good clinical efficacy.

The clincial analysis of 7 ankylosing spondylitis patients with adverse cutaneous reactions to infliximab

Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

Matrix metalloproteinase-3 and-9 : possible biomarkers of infliximab efficacy in ankylosing spondylitis ( AS ) ?

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Efficacy of Yishen Juanbi Oill on Ankylosing Spondylitis

Clinical efficacy of infliximab in the treatment of 62 cases with Crohn's disease

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

Infliximab Monotherapy for Chinese Patients with Moderate to Severe Plaque Psoriasis: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial.

P1086 Re-administration of infliximab in patients with extremely refractory perianal Crohn’s disease

Preliminary Study on Treatment of Crohn's Disease with Infliximab

Recombinant Human Tumor Necrosis Factor Receptor Type Ⅱ - IgG Fc Fusion Protein for the Treatment of Moderate to Severe Psoriasis Vulgaris:A Multicenter, Randomized, Parallel-Group, Controlled Clinical Trial

Analysis of Adverse Drug Reactions of Azathioprine in the Treatment of Patients with Inflammatory Bowel Disease

P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study

Study of therapeutic effects of infliximab on bone in patients with ankylosing spondylitis using ultrasonography

A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease

Safety of TNF-α inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database

Clinical application of Infliximab trough concentration and anti-drug antibody detection in the treatment of Crohn′s disease

Adverse events of anti-tumour necrosis factor therapy for ankylosing spondylitis: a retrospective study of 369 Chinese Han population

P1058 Safety and effectiveness of subcutaneous infliximab formulation in difficult-to-treat Crohn’s Disease patients with previous exposure to intravenous infliximab: A case-series

Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature

Efficacy and survival of infliximab in psoriasis patients: A single‐center experience in China